文献速递泌尿男性生殖肿瘤

Xaluritamig:靶向STEAP1×CD3的XmAb 2+1免疫疗法治疗转移性去势抵抗性前列腺癌——首次人体研究剂量探索结果

Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study.
PubMed 文献 · Cancer Discov · 2024-01-01

Xaluritamig(AMG 509)是靶向STEAP1的T细胞衔接器,用于晚期前列腺癌。本次首次人体研究纳入97例转移性去势抵抗性前列腺癌患者(多为紫杉类经治),接受每周或每两周静脉给药0.001至2.0 mg,最大耐受剂量为每周1.5 mg静脉给药(三步剂量)。最常见治疗相关不良事件为细胞因子释放综合征(72%)、疲乏(45%)和肌痛(34%)。总体PSA50应答率49%、客观缓解率24%,目标剂量≥0.75 mg组PSA50应答率59%、客观缓解率41%。

要点

  • Xaluritamig治疗mCRPC总体PSA50应答率49%、ORR 24%,目标剂量≥0.75 mg组分别为59%和41%。
  • 最大耐受剂量为每周1.5 mg静脉给药(三步剂量),最常见治疗相关不良事件为CRS(72%)。
  • CRS主要发生于第1周期,经预给药和分步剂量后改善。

核心结论

  • Xaluritamig是一种新型前列腺癌免疫疗法,显示出令人鼓舞的结果并支持进一步开发。
  • 与晚期mCRPC历史既定治疗相比,Xaluritamig显示出令人鼓舞的PSA和RECIST应答。

研究设计与样本

  • 首次人体研究,报告转移性去势抵抗性前列腺癌患者的单药剂量探索结果,患者主要为紫杉类经治。
  • 97例患者接受至少1次静脉给药,剂量范围0.001至2.0 mg,每周或每两周给药。

主要发现

  • 最大耐受剂量为每周1.5 mg静脉给药(三步剂量)。
  • 最常见治疗相关不良事件为细胞因子释放综合征(72%)、疲乏(45%)和肌痛(34%)。
  • CRS主要发生于第1周期,经预给药和分步剂量后改善。
  • 各队列PSA50应答率49%、客观缓解率24%;目标剂量≥0.75 mg组PSA50应答率59%、客观缓解率41%。

关键数值与推荐

  • 剂量范围:0.001至2.0 mg,每周或每两周静脉给药。
  • 最大耐受剂量:每周1.5 mg静脉给药(三步剂量)。
  • 总体PSA50应答率49%,客观缓解率24%。
  • 目标剂量≥0.75 mg组PSA50应答率59%,客观缓解率41%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

UNLABELLED: Xaluritamig (AMG 509) is a six-transmembrane epithelial antigen of the prostate 1 (STEAP1)-targeted T-cell engager designed to facilitate lysis of STEAP1-expressing cancer cells, such as those in advanced prostate cancer. This first-in-human study reports monotherapy dose exploration for patients with metastatic castration-resistant prostate cancer (mCRPC), primarily taxane pretreated. Ninety-seven patients received ≥1 intravenous dose ranging from 0.001 to 2.0 mg weekly or every 2 weeks. MTD was identified as 1.5 mg i.v. weekly via a 3-step dose. The most common treatment-related adverse events were cytokine release syndrome (CRS; 72%), fatigue (45%), and myalgia (34%). CRS occurred primarily during cycle 1 and improved with premedication and step dosing. Prostate-specific antigen (PSA) and RECIST responses across cohorts were encouraging [49% PSA50; 24% objective response rate (ORR)], with greater frequency at target doses ≥0.75 mg (59% PSA50; 41% ORR). Xaluritamig is a novel immunotherapy for prostate cancer that has shown encouraging results supporting further development. SIGNIFICANCE: Xaluritamig demonstrated encouraging responses (PSA and RECIST) compared with historical established treatments for patients with late-line mCRPC. This study provides proof of concept for T-cell engagers as a potential treatment for prostate cancer, validates STEAP1 as a target, and supports further clinical investigation of xaluritamig in prostate cancer. See related commentary by Hage Chehade et al., p. 20. See related article by Nolan-Stevaux et al., p. 90. This article is featured in Selected Articles from This Issue, p. 5.

来源:Cancer Discov,查看原文。版权归原作者所有。

引用

  1. Kelly WK, Danila DC, Lin CC, et al. Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study. Cancer Discov. 2024. PMID: 37861461. doi:10.1158/2159-8290.CD-23-0964

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。